Allyson T. Gage

Dr. Allyson T. Gage is a neuroscientist and drug development executive, who has over 18 years of experience leading teams in all phases of clinical development. She has been responsible for the overall strategic

and clinical development of small molecules, biologics, and cellular therapies for the treatment of central nervous

system disorders, including depression, alcohol dependence, Alzheimer’s dementia, neuropathic pain, traumatic brain injury, and spinal cord injury. Allyson has a proven track record in partnering with therapeutic area clinicians, US and International regulators, patient groups, and data scientists to translate pre-clinical information into human evaluation, to design informative clinical trial protocols, and ensure a regulatory path with approvable and clinically meaningful outcome measures. Prior to joining Cohen Veterans Bioscience, Allyson’s most recent experience was focused in the field of regenerative medicine, working toward the development of a therapeutic for spinal cord injury.

Allyson earned her BA from Rutgers College in New Brunswick, NJ and her MS and PhD in neuroscience from Albert Einstein College of Medicine, New York.